GLP-1 Microdosing: What It Is, Who Is Selling It, and What the Evidence Actually Shows

Reviewed by Donald L. Gates, MD — Bariatric Medicine, practicing since 1999

If you have spent time researching weight loss medications online in the past year or two, you have likely encountered the term “microdosing GLP-1.” It is being marketed by compounding pharmacies, direct-to-consumer telehealth platforms, and social media influencers as a gentler, more affordable approach to GLP-1 therapy. Before you decide whether it is right for you, you deserve a clear-eyed look at what microdosing actually means, what evidence exists for it, and how Scale Solutions approaches the question of dose individualization in clinical practice.

What Is GLP-1 Microdosing?

In the context of weight loss medications, “microdosing” refers to using GLP-1 receptor agonists at doses substantially below the therapeutic ranges established in clinical trials. For semaglutide, the FDA-approved treatment doses range from 0.5mg weekly (starting dose for Ozempic) up to 2.4mg weekly (maximum for Wegovy). Microdosing as commonly marketed involves doses such as 0.125mg, 0.25mg, or similar sub-therapeutic amounts — often framed as a “starting point” or a permanent lower-dose protocol.

This is distinct from the standard titration schedule, which begins at low doses and increases over several months to therapeutic range. Microdosing, as marketed, implies either staying permanently at sub-therapeutic doses or using them as an indefinite maintenance strategy — not as a ramp-up phase.

Who Is Marketing Microdose GLP-1?

The microdosing market has been driven primarily by compounding pharmacies and the telehealth platforms that partner with them. During the period when branded semaglutide (Ozempic, Wegovy) was on the FDA shortage list — from roughly 2022 through early 2025 — compounding pharmacies were legally permitted to produce semaglutide under FDA shortage provisions. Some of those pharmacies developed proprietary “microdose” formulations, often bundled with other compounds such as B12, NAD+, or other additives.

Telehealth platforms including Found, Noom Med, Henry Meds, and others have offered microdose or low-dose GLP-1 protocols, typically at lower monthly costs than branded medications. The marketing often emphasizes reduced side effects, gentler onset, and lower price — all of which are real advantages worth acknowledging honestly.

The Evidence: What We Know and What We Do Not

The clinical trial evidence base for GLP-1 medications — the STEP trials for semaglutide, SURMOUNT trials for tirzepatide — was conducted at standard therapeutic doses. The weight loss outcomes that made these medications famous (15-20% body weight loss in the highest-quality trials) were produced at approved therapeutic doses, typically 2.4mg semaglutide weekly or 15mg tirzepatide weekly.

There are no large, randomized controlled trials specifically evaluating sub-therapeutic or microdose GLP-1 protocols for weight loss. The evidence that exists is:

• Anecdotal reports from patients and prescribers
• Small observational case series
• Theoretical pharmacological arguments based on dose-response modeling
• Marketing materials from commercial entities with financial incentives

This does not mean microdosing is without any effect. GLP-1 receptors are dose-responsive, and even low-dose activation may produce some degree of appetite modification, gastric slowing, and glucose regulation. But the magnitude of effect at sub-therapeutic doses is almost certainly lower — and in many cases substantially lower — than at the proven doses. Patients choosing microdose protocols should have realistic expectations about the degree of weight loss they are likely to achieve.

Why Some Patients Prefer Microdosing

The preference for microdosing is not irrational. Patients who choose this approach often do so for legitimate reasons:

• Side effect tolerance: Nausea, vomiting, and GI distress are common at higher doses of GLP-1 medications, particularly during dose escalation. Some patients find that staying at lower doses allows them to maintain quality of life while still experiencing some benefit. This is a reasonable trade-off for some patients.
• Cost: Compounded semaglutide at microdose levels is significantly less expensive than branded medications. For patients without insurance coverage, the cost differential is substantial.
• Perceived “natural” approach: Some patients are philosophically uncomfortable with using a medication at its maximum approved dose and prefer a more conservative approach. This is a valid patient preference to discuss openly.
• Maintenance strategy: As discussed in our page on what happens when you stop GLP-1 therapy, microdosing is sometimes used as a post-goal maintenance protocol. This is different from using microdoses for initial weight loss and may have different risk-benefit considerations.

The Regulatory and Legal Context as of 2026

This is an area where the landscape changed significantly in early 2025. The FDA removed semaglutide from its drug shortage list in February 2025, which eliminated the legal basis for compounding pharmacies to produce copies of branded semaglutide under shortage provisions. The FDA subsequently issued guidance making clear that compounding of semaglutide for the purpose of weight loss — outside of patient-specific 503A compounding for documented individual needs — is no longer generally permissible.

503A compounding pharmacies (traditional patient-specific compounders) may still produce semaglutide for individual patients with documented contraindications to commercial products or other specific clinical justifications, but the broad commercial compounding that fueled the microdose market is legally on shakier ground as of this writing. 503B outsourcing facilities (larger compounders serving multiple facilities) are subject to even stricter FDA oversight regarding what they may and may not produce.

Patients should be aware that the regulatory environment for compounded GLP-1 products is actively evolving. Sourcing compounded medications from operations of uncertain regulatory standing carries risk — both to health (quality control varies significantly across compounders) and to access (supply disruptions can occur suddenly).

For current information on access and cost for both branded and compounded options, see our page on GLP-1 cost and insurance in Georgia, and watch for our updated analysis of the GLP-1 shortage situation in Georgia for 2026.

The Scale Solutions Position on Dose Individualization

Dr. Gates does not use a one-size-fits-all titration protocol. Individualized titration — moving patients up the dose ladder at a pace they can tolerate, holding at doses that produce benefit without unacceptable side effects, and not automatically pushing to the maximum approved dose — is standard practice here.

For patients who cannot tolerate standard titration due to side effects, Dr. Gates is willing to titrate down or maintain at lower doses for tolerability. For patients who achieve meaningful benefit at a lower dose and do not require further escalation, staying at that dose rather than chasing the maximum is appropriate clinical judgment.

What Dr. Gates will be transparent about is the following: if you are at a sub-therapeutic dose, your expected weight loss is lower than the trial data suggests, and the degree of benefit is difficult to predict in the absence of trial data at those doses. Patients deserve to know that distinction clearly, rather than having it obscured by marketing language about “personalized” or “gentle” protocols.

For patients interested in the full range of GLP-1 treatment options available at Scale Solutions, our semaglutide overview covers the standard medication in detail. For questions about Dr. Gates’s clinical philosophy and approach, visit the about Dr. Gates page.

Questions to Ask Before Starting a Microdose Protocol

If you are considering a microdose GLP-1 protocol from any provider, here are the questions worth asking:

1. What specific dose am I being prescribed, and how does it compare to the doses studied in clinical trials?
2. Is the medication compounded or commercially manufactured? What is the regulatory status of the compounder?
3. What weight loss outcome should I realistically expect at this dose, based on available evidence?
4. What is the plan if I do not respond adequately at this dose? Is there a titration path?
5. How is my overall health being monitored — labs, blood pressure, metabolic markers?
6. What happens if I have a side effect or need to escalate care?

Physician-led, in-person care — where a provider who knows your full medical history is making dose decisions based on your labs and clinical presentation — is the context in which these questions get answered most thoroughly.

This page is for informational purposes only and is not medical advice. Consult Dr. Gates or another qualified clinician before starting any treatment.